225 related articles for article (PubMed ID: 32161142)
1. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
2. SKP2 My Lou, My Darling.
Lambert SL; Jones KB
Cancer Res; 2020 Jun; 80(12):2437-2438. PubMed ID: 32540853
[TBL] [Abstract][Full Text] [Related]
3. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
[TBL] [Abstract][Full Text] [Related]
5. Systematic screening identifies a 2-gene signature as a high-potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma.
Hu Q; Zhou S; Hu X; Zhang H; Huang S; Wang Y
J Cell Mol Med; 2020 Jan; 24(1):1010-1021. PubMed ID: 31742892
[TBL] [Abstract][Full Text] [Related]
6. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
7. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics.
Li CF; Wang JM; Kang HY; Huang CK; Wang JW; Fang FM; Wang YH; Wu WR; Li SH; Yu SC; Lee JC; Lan J; Shiue YL; Wu LC; Huang HY
Clin Cancer Res; 2012 Mar; 18(6):1598-610. PubMed ID: 22322669
[TBL] [Abstract][Full Text] [Related]
8. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
[TBL] [Abstract][Full Text] [Related]
9. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
Crago AM; Cardona K; Koseła-Paterczyk H; Rutkowski P
Surg Oncol Clin N Am; 2022 Jul; 31(3):419-430. PubMed ID: 35715142
[TBL] [Abstract][Full Text] [Related]
10. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.
Griewank KG; Wiesner T; Murali R; Pischler C; Müller H; Koelsche C; Möller I; Franklin C; Cosgarea I; Sucker A; Schadendorf D; Schaller J; Horn S; Brenn T; Mentzel T
Mod Pathol; 2018 Mar; 31(3):418-428. PubMed ID: 29099504
[TBL] [Abstract][Full Text] [Related]
11. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review.
Yoshimoto M; Yamada Y; Ishihara S; Kohashi K; Toda Y; Ito Y; Yamamoto H; Furue M; Nakashima Y; Oda Y
Am J Surg Pathol; 2020 Jan; 44(1):87-97. PubMed ID: 31651522
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the Genomic Basis of Chemosensitivity in Sarcomas of the Extremities: An Integrated Approach for an Unmet Clinical Need.
Vanni S; Fausti V; Fonzi E; Liverani C; Miserocchi G; Spadazzi C; Cocchi C; Calabrese C; Gurrieri L; Riva N; Recine F; Casadei R; Pieri F; Guerrieri AN; Serra M; Ibrahim T; Mercatali L; De Vita A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108089
[TBL] [Abstract][Full Text] [Related]
13. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.
Conley AP; Wang WL; Livingston JA; Ravi V; Tsai JW; Ali A; Ingram DR; Lowery CD; Roland CL; Somaiah N; Hwu P; Yee C; Subbiah V; Futreal A; Lazar AJ; Patel S; Roszik J
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31096717
[TBL] [Abstract][Full Text] [Related]
14. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma.
Iwata S; Yonemoto T; Araki A; Ikebe D; Kamoda H; Hagiwara Y; Ishii T
J Surg Oncol; 2014 Nov; 110(6):707-11. PubMed ID: 24975462
[TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome.
Ono T; Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Akiyama T; Sugaya J; Fukushima S; Kojima N; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 Mar; 35(2):756-766. PubMed ID: 35118583
[TBL] [Abstract][Full Text] [Related]
17. Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications.
Pestana RC; Roszik J; Groisberg R; Sen S; Van Tine BA; Conley AP; Subbiah V
Curr Probl Cancer; 2021 Oct; 45(5):100794. PubMed ID: 34656365
[TBL] [Abstract][Full Text] [Related]
18. Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma.
Sun H; Liu J; Hu F; Xu M; Leng A; Jiang F; Chen K
Front Genet; 2023; 14():1109491. PubMed ID: 36873946
[TBL] [Abstract][Full Text] [Related]
19. Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency.
Choi J; Curtis SJ; Roy DM; Flesken-Nikitin A; Nikitin AY
Am J Pathol; 2010 Nov; 177(5):2645-58. PubMed ID: 20864684
[TBL] [Abstract][Full Text] [Related]
20. The landscape of genetic aberrations in myxofibrosarcoma.
Takeuchi Y; Yoshida K; Halik A; Kunitz A; Suzuki H; Kakiuchi N; Shiozawa Y; Yokoyama A; Inoue Y; Hirano T; Yoshizato T; Aoki K; Fujii Y; Nannya Y; Makishima H; Pfitzner BM; Bullinger L; Hirata M; Jinnouchi K; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Okamoto T; Haga H; Ogawa S; Damm F
Int J Cancer; 2022 Aug; 151(4):565-577. PubMed ID: 35484982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
